1
|
Séguy L, Daressy F, Lahlil S, Corvaisier S, Dumontet V, Litaudon M, Apel C, Roussi F, Wiels J, Robert A, Groo AC, Malzert-Fréon A. In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration. Int J Pharm 2023; 630:122433. [PMID: 36436745 DOI: 10.1016/j.ijpharm.2022.122433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/18/2022] [Accepted: 11/19/2022] [Indexed: 11/27/2022]
Abstract
MCL-1, an anti-apoptotic member of the BCL-2 protein family, is overexpressed in many types of cancer and contributes to chemotherapy resistance. The drimane derivative NA1-115-7 is a natural compound isolated from Zygogynum pancheri that can be considered as a very promising lead for treating MCL-1-dependent hematological malignancies. As this drug suffers from low stability in acidic conditions and poor aqueous solubility, we evaluated the potential oral use of NA1-115-7 by encapsulating it in lipid nanoemulsions (NA-NEs) prepared by spontaneous emulsification. NA-NEs showed a particle size of 41.9 ± 2.2 nm, PDI of 0.131 ± 0.016, zeta potential of -5.8 ± 3.4 mV, encapsulation efficiency of approximately 100 % at a concentration of 24 mM. The stability of NA-1-115-7 was sixfold higher than that of the unencapsulated drug in simulated gastric fluid. NA-NEs significantly restored apoptosis and halved the effective doses of NA1-115-7 on BL2, a Burkitt lymphoma cell line, without toxicity in normal cells. Such a drug-delivery system appears to be particularly interesting for the oral administration of NA1-115-7, as it improves its solubility and stability, as well as efficacy, by reducing the therapeutic dose, making it possible to further consider in-vivo studies of this promising drug in BL2 xenografted mice.
Collapse
Affiliation(s)
- Line Séguy
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France
| | - Florian Daressy
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France; UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | - Sophia Lahlil
- UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | | | - Vincent Dumontet
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Marc Litaudon
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Cécile Apel
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Fanny Roussi
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Joëlle Wiels
- UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | - Aude Robert
- UMR1279 INSERM, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif Cedex, France
| | | | | |
Collapse
|
2
|
Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment. Pharmaceutics 2021; 13:pharmaceutics13101626. [PMID: 34683919 PMCID: PMC8540544 DOI: 10.3390/pharmaceutics13101626] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 09/29/2021] [Accepted: 10/01/2021] [Indexed: 12/13/2022] Open
Abstract
Background and Purpose: The activation of 5-HT4 receptors with agonists has emerged as a valuable therapeutic strategy to treat Alzheimer’s disease (AD) by enhancing the nonamyloidogenic pathway. Here, the potential therapeutic effects of tegaserod, an effective agent for irritable bowel syndrome, were assessed for AD treatment. To envisage its efficient repurposing, tegaserod-loaded nanoemulsions were developed and functionalized by a blood–brain barrier shuttle peptide. Results: The butyrylcholinesterase inhibitory activity of tegaserod and its neuroprotective cellular effects were highlighted, confirming the interest of this pleiotropic drug for AD treatment. In regard to its drugability profile, and in order to limit its peripheral distribution after IV administration, its encapsulation into monodisperse lipid nanoemulsions (Tg-NEs) of about 50 nm, and with neutral zeta potential characteristics, was performed. The stability of the formulation in stock conditions at 4 °C and in blood biomimetic medium was established. The adsorption on Tg-NEs of peptide-22 was realized. The functionalized NEs were characterized by chromatographic methods (SEC and C18/HPLC) and isothermal titration calorimetry, attesting the efficiency of the adsorption. From in vitro assays, these nanocarriers appeared suitable for enabling tegaserod controlled release without hemolytic properties. Conclusion: The developed peptide-22 functionalized Tg-NEs appear as a valuable tool to allow exploration of the repurposed tegaserod in AD treatment in further preclinical studies.
Collapse
|
4
|
Groo AC, Hedir S, Since M, Brotin E, Weiswald LB, Paysant H, Nee G, Coolzaet M, Goux D, Delépée R, Freret T, Poulain L, Voisin-Chiret AS, Malzert-Fréon A. Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer. Int J Pharm 2020; 587:119655. [PMID: 32712252 DOI: 10.1016/j.ijpharm.2020.119655] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 06/26/2020] [Accepted: 07/13/2020] [Indexed: 01/22/2023]
Abstract
BACKGROUND Pyridoclax is an original lead, recently identified as very promising in treatment of chemoresistant ovarian cancers. To correct the unfavorable intrinsic physico-chemical properties of this BCS II drug, a formulation strategy was implied in the drug discovery step. Pyridoclax-loaded nanoemulsions (NEs) were developed to permit its preclinical evaluation. RESULTS The resulting nanoemulsions displayed a mean size of about 100 nm and a high encapsulation efficiency (>95%) at a drug loading of 2 wt%, enabling a 1,000-fold increase of the Pyridoclax apparent solubility. NEs have enabled a sustained release of the drug as assayed by a dialysis bag method. In addition, anti-tumor effects of the Pyridoclax-loaded nanoemulsions (PNEs) showed a 2.5-fold higher activity on chemoresistant ovarian cancer cells than free Pyridoclax. This effect was confirmed by a drastic increase of caspase 3/7 activation from 10 µM PNEs, as newly objectified by real time apoptose imaging. The Pyridoclax bioavailability was kept unchanged after encapsulation in nanoemulsions as determined in a mice model after oral administration. CONCLUSION Thus, NEs should permit valuable Pyridoclax oral administration, and valorization of this promising anticancer drug by maintaining its original anticancer activity, and by reducing the Pyridoclax therapeutic concentration.
Collapse
Affiliation(s)
- A C Groo
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France.
| | - S Hedir
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - M Since
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France
| | - E Brotin
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France; Normandie Univ, UNICAEN, SF4206 Icore, ImpedanCELL Platform, 14000 Caen, France
| | - L-B Weiswald
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - H Paysant
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - G Nee
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - M Coolzaet
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - D Goux
- Normandie Univ, UNICAEN, CMAbio(3), SF4206 Icore, 14000 Caen, France
| | - R Delépée
- Normandie Univ, UNICAEN, PRISMM Platform, SF4206 ICORE, Comprehensive Cancer Center F. Baclesse, 14000 Caen, France
| | - T Freret
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - L Poulain
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | | | | |
Collapse
|